Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) EBT: 2019-2024

Historic EBT for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$193.3 million.

  • Nurix Therapeutics' EBT fell 76.82% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.0 million, marking a year-over-year decrease of 38.09%. This contributed to the annual value of -$193.3 million for FY2024, which is 34.28% down from last year.
  • Per Nurix Therapeutics' latest filing, its EBT stood at -$193.3 million for FY2024, which was down 34.28% from -$143.9 million recorded in FY2023.
  • Nurix Therapeutics' EBT's 5-year high stood at -$63.8 million during FY2020, with a 5-year trough of -$193.3 million in FY2024.
  • Over the past 3 years, Nurix Therapeutics' median EBT value was -$180.4 million (recorded in 2022), while the average stood at -$172.5 million.
  • In the last 5 years, Nurix Therapeutics' EBT tumbled by 197.19% in 2020 and then climbed by 20.19% in 2023.
  • Yearly analysis of 5 years shows Nurix Therapeutics' EBT stood at -$63.8 million in 2020, then slumped by 83.55% to -$117.1 million in 2021, then slumped by 54.07% to -$180.4 million in 2022, then climbed by 20.19% to -$143.9 million in 2023, then slumped by 34.28% to -$193.3 million in 2024.